What are the indications, dosing recommendations, and contraindications for sotalol compared with metoprolol in treating hypertension, angina, heart failure, and arrhythmias?

Sotalol vs Metoprolol: Clinical Comparison

For arrhythmia management in structural heart disease, sotalol and metoprolol serve fundamentally different roles: metoprolol (or other evidence-based beta-blockers like carvedilol/bisoprolol) is first-line for mortality reduction and VT/VF prevention, while sotalol is reserved as add-on antiarrhythmic therapy when beta-blockers alone fail to suppress recurrent ventricular or supraventricular arrhythmias.

Key Clinical Distinctions

Mechanism and Classification

• Metoprolol: Selective beta-1 blocker (Class II antiarrhythmic) with proven mortality benefit in heart failure and post-MI patients 1
• Sotalol: Non-selective beta-blocker PLUS Class III antiarrhythmic (potassium channel blocker) that prolongs QT interval 2, 3

Primary Indications

Metoprolol is indicated for:

• Hypertension (first-line)
• Angina pectoris
• Heart failure with reduced ejection fraction (mortality reduction) 1
• Post-myocardial infarction (mortality reduction)
• Rate control in atrial fibrillation
• First-line prevention of VT/VF in structural heart disease 2

Sotalol is indicated for:

• Maintenance of sinus rhythm in atrial fibrillation/flutter (when beta-blockers, diltiazem, or verapamil fail) 4
• Suppression of ventricular tachycardia/fibrillation as add-on therapy to beta-blockers in patients with ICDs 2
• Supraventricular tachycardia refractory to other agents 4

Critical Safety Differences

Sotalol Contraindications (Absolute) 3

• QTc >450 msec at baseline (proarrhythmia risk)
• Creatinine clearance <40 mL/min
• Severe heart failure (LVEF <20% or NYHA Class III-IV) 2
• Sinus bradycardia <50 bpm
• Second or third-degree AV block without pacemaker
• Hypokalemia (<4 mEq/L)
• Bronchial asthma

Metoprolol Cautions

• Severe heart failure requires specialist initiation and slow titration 1
• Bradycardia <60 bpm
• Obstructive pulmonary disease (relative contraindication)

Arrhythmia Management Algorithm

For Ventricular Tachycardia/Fibrillation with Structural Heart Disease

Step 1: Optimize beta-blocker therapy (metoprolol, carvedilol, or bisoprolol) to maximally tolerated dose 2

Step 2: If VT/VF recurs despite optimized beta-blocker:

• Add sotalol OR amiodarone as first-line antiarrhythmic 2
• Sotalol preferred if long-term toxicity is a concern (more favorable profile than amiodarone) 2
• Amiodarone preferred for electrical storm or severe heart failure (LVEF <20%) 2

Step 3: If antiarrhythmic drug therapy fails, proceed to catheter ablation 2

For Supraventricular Tachycardia

First-line: Beta-blockers (metoprolol), diltiazem, or verapamil 4

Second-line: Sotalol may be reasonable if first-line agents fail and patient has no structural heart disease 4

For Atrial Fibrillation

Rate control: Metoprolol is first-line 5, 6

Rhythm control: Sotalol can maintain sinus rhythm but requires careful monitoring 5, 4, 7

Dosing Protocols

Metoprolol Dosing 1

• Starting dose: 12.5-25 mg once daily (extended-release)
• Target dose: 200 mg once daily
• Titrate every 2 weeks, doubling dose until target reached
• Monitor heart rate, blood pressure, signs of congestion

Sotalol Dosing (Requires Hospitalization for Initiation) 3

Mandatory pre-initiation requirements:

1. Baseline QTc must be ≤450 msec
2. Calculate creatinine clearance
3. Correct hypokalemia to >4 mEq/L
4. Continuous ECG monitoring for minimum 3 days

Dosing by renal function:

• CrCl >60 mL/min: Start 80 mg twice daily
• CrCl 40-60 mL/min: Start 80 mg once daily
• CrCl <40 mL/min: Contraindicated

Monitoring protocol:

• Check QT interval 2-4 hours after each dose
• If QT ≥500 msec: Reduce dose or discontinue
• Can titrate to 120 mg BID, then 160 mg BID if needed (maximum dose)

Comparative Efficacy Data

Post-CABG Atrial Fibrillation Prevention

Sotalol superior to metoprolol: AF occurred in 16% with sotalol vs 32% with metoprolol (p<0.01) 8

Ventricular Arrhythmia Suppression in ICD Patients

Conflicting evidence:

• One study showed metoprolol superior: 80% freedom from VT at 2 years vs 51% with sotalol (p=0.016) 9
• Another study showed no significant difference between agents 10

Clinical interpretation: Both agents reduce VT/VF recurrence when added to ICD therapy, but metoprolol has better tolerability (discontinuation rate 5.3% vs 23.5% for sotalol) 2

Common Pitfalls

With Sotalol

1. Outpatient initiation is dangerous: Requires inpatient monitoring due to proarrhythmia risk 3
2. QT monitoring inadequacy: Must measure QT 2-4 hours post-dose, not just at trough
3. Renal function changes: Sotalol is renally cleared; deteriorating renal function mandates dose reduction
4. Use in heart failure: Higher proarrhythmia risk in LVEF <20%; avoid unless ICD present 2
5. Combination with other beta-blockers: Can be used together, but monitor for excessive bradycardia 2

With Metoprolol

1. Abrupt discontinuation: Can precipitate rebound ischemia or arrhythmias
2. Inadequate dosing: Many patients receive subtherapeutic doses; titrate to target or maximally tolerated dose 1
3. Heart failure initiation: May cause temporary worsening; start low, go slow, increase diuretics if congestion develops 1

Heart Failure Considerations

Metoprolol CR/XL reduces mortality in heart failure and is strongly recommended 1

Sotalol in heart failure:

• Higher discontinuation rates (23.5% vs 5.3% for other beta-blockers) 2
• Increased proarrhythmia risk with LVEF <20% 2
• Should be avoided in severe heart failure unless ICD present 2
• No mortality benefit demonstrated 11

Practical Selection Guide

Choose Metoprolol when:

• Treating hypertension, angina, or heart failure
• Post-MI patient
• First-line VT/VF prevention needed
• Patient has severe LV dysfunction
• Long-term therapy anticipated

Choose Sotalol when:

• Recurrent VT/VF despite optimized beta-blocker therapy
• Maintaining sinus rhythm in atrial fibrillation (after other agents fail)
• Patient has ICD and needs additional arrhythmia suppression
• Structural heart disease is absent or mild (LVEF >40%)
• Can ensure proper QT monitoring and hospitalization for initiation

Never use sotalol as monotherapy for heart failure or as first-line VT/VF prevention—beta-blockers like metoprolol provide mortality benefit that sotalol does not 2, 11.